Pharmaceuticals Acquisitions in New York
New York Pharma Deals and Themes
New York shows up repeatedly across pharmaceuticals deals ranging from completed acquisitions to growth and platform investments. Across recent transactions, buyers in the biopharma, specialty pharma, and OTC space focus on adding pipeline assets, expanding dosage/formulation capabilities, or scaling distribution reach.
Several deals connect to rare disease and CNS innovation, including Cycle Group Holdings Limited (Cycle Pharmaceuticals Ltd) acquiring clinical-stage Applied Therapeutics, Inc. and Axsome’s acquisition of Baergic Bio to secure exclusive global rights to AZD7325. Other transactions emphasize broader commercialization and manufacturing scale—such as investments supporting private-label OTC growth in Long Island and expanding liquid dosage capabilities in upstate New York.
The geography is consistently anchored in New York, with transactions involving Long Island and upstate locations, and with recurring investor participation from healthcare-focused firms like Axsome Therapeutics, PharmaCyte Biotech, Inc., RF Investment Partners, and Biocodex Group.
What Stands Out
- Rare-disease and CNS pipeline expansion appears in New York-related activity, including Cycle Pharmaceuticals (govorestat and rare metabolic disease focus) and Axsome’s AZD7325 rights.
- Global rights and licensing strategy are central in some deals, such as Axsome securing exclusive worldwide rights via an amended license tied to AstraZeneca’s AZD7325.
- Manufacturing and formulation capability build-outs show up in OTC and specialty pharma transactions (e.g., liquid dosage forms and additional packaging lines).
- Veterinary/companion animal and women’s/digestive health are recurring subsector interests, including a platform investment in Altro Pharmaceuticals and Amici Pharmaceuticals and Biocodex’s majority stake in Hilma.
- New York clustering includes Long Island and upstate New York targets and facilities, along with at least one Massena-based manufacturing operation referenced in the PurinePharma acquisition.
-
- Buyer
- Axsome Therapeutics
- Target
- Baergic Bio
- Seller
- Avenue Therapeutics, Baergic Bio shareholders
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Buyout
Axsome Therapeutics acquired a 100% equity interest in Baergic Bio (a subsidiary of Avenue Therapeutics) and amended Baergic Bio's license with AstraZeneca to obtain exclusive global rights to AZD7325, an early‑stage selective GABAA α2,3 receptor modulator for epilepsy. The deal includes a $0.3 million upfront payment to Baergic Bio shareholders and potential development, regulatory, sales‑based milestones and tiered royalties to Avenue Therapeutics and AstraZeneca as described in the purchase and amended license agreements.
-
September 2, 2025
- Buyer
- PharmaCyte Biotech, Inc.
- Target
- TNF Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Growth capital
PharmaCyte Biotech, Inc. increased its equity stake in TNF Pharmaceuticals, Inc. by $3.0 million to support TNF's recent license agreement with LightSolver for a light-based compute accelerator intended for cryptocurrency and blockchain applications. The investment is positioned to help TNF execute a strategic pivot tied to the new license; PharmaCyte said it remains well-capitalized and may pursue further portfolio opportunities.
-
September 19, 2024
- Buyer
- RF Investment Partners, Aquimont Capital, Miramar Equity Partners
- Target
- Altro Pharmaceuticals, Amici Pharmaceuticals
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Growth capital
RF Investment Partners announced a platform investment in Long Island-based sister companies Altro and Amici Pharmaceuticals, partnering with Aquimont Capital and Miramar Equity Partners to support growth in the companion animal/veterinary pharmaceutical market. The investment provides flexible debt and equity capital to expand sourcing, manufacturing and distribution capabilities for generic pharmaceuticals that serve both veterinary and human end markets.
-
November 17, 2022
- Buyer
- Biocodex Group
- Target
- Hilma
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Buyout
French pharmaceutical group Biocodex has acquired a majority stake in Hilma, a U.S.-based natural remedies start-up founded by Hilary Quartner, Nina Mullen and Lily Galef. The deal gives Biocodex a stronger foothold in the U.S. digestive-health and women’s-health segments and will help scale Hilma’s omnichannel retail strategy (DTC plus 750+ stores including Target).
-
September 7, 2022
- Buyer
- SK Capital Partners, Comvest Partners
- Target
- VanDeMark Chemical, Inc.
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Growth capital
Funds advised by SK Capital Partners have made a strategic investment in VanDeMark Chemical, a Comvest Partners portfolio company headquartered in Lockport, New York. Comvest remains a co-owner; the investment will accelerate VanDeMark's growth and deepen its focus on life-science specialty chemistries, with SK Capital supporting organic and inorganic expansion.
-
April 27, 2021
- Buyer
- NewSpring Mezzanine (NewSpring Capital), Tecum Capital (Tecum Capital Partners), Leedon Park Capital LLC, PNC Bank (PNC Financial Services Group)
- Target
- Spirit Pharmaceuticals LLC
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Growth capital
An investor group led by NewSpring Mezzanine, alongside Tecum Capital, Leedon Park Capital and PNC Bank provided a growth capital injection into Spirit Pharmaceuticals LLC, backing CEO and founder Ajoy Joshi. The funding will support the Long Island-based private-label developer, packager and distributor of over-the-counter pharmaceutical products as it expands capacity (two additional facilities, 11 packaging lines) and deepens relationships with big-box retailers, medical distributors and e-commerce customers.
-
November 9, 2015
- Buyer
- Geritrex, BelHealth Investment Partners
- Target
- PurinePharma
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Addon
Geritrex, a BelHealth Investment Partners portfolio company, has acquired the business and assets of PurinePharma, a private-label manufacturer and distributor of OTC liquid nasal, allergy, and cough & cold products based in Massena, New York. The add-on expands Geritrex's manufacturing capabilities into liquid dosage forms, provides access to the retail private-label channel and export markets, and adds a CGMP-approved manufacturing facility in upstate New York.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.
Frequently Asked Questions
What types of pharmaceuticals deals are shown for New York?
The page covers acquisitions and investment transactions across biopharma pipeline expansion, licensing for specific drug programs, and scale-up efforts in OTC and specialty pharmaceuticals.
Which New York-focused themes appear most often in these transactions?
Recurring themes include rare-disease/CNS pipeline additions, global rights secured through licensing amendments, and manufacturing or distribution capacity expansion—often tied to OTC private-label or specialty segments.
Do the deals involve only biopharma, or are OTC and specialty pharma included?
OTC and specialty pharma activity is included, including private-label packagers/distributors and additions to manufacturing capabilities such as liquid dosage forms and expanded packaging lines.
Where are the New York locations referenced in these transactions?
The page references New York, including Long Island and upstate New York locations such as Lockport and Massena.